Compass Therapeutics Q2 net loss $11.3M; BTC top-line data pushed to H2 2024

Compass Therapeutics, Inc.

Net loss of $11.3M ($0.09/share) in Q2 2023 vs $8.5M loss ($0.08/share) in Q2 2022.
Cash and marketable securities $169M as of June 30, 2023; cash runway into 2026.
R&D expense $10.2M in Q2 2023, up 74% YoY driven by CTX-009 clinical and manufacturing costs.
CTX-009 Phase 2 CRC initial data still expected H2 2023; BTC top-line data delayed to H2 2024 due to slower enrollment.
CTX-8371 (PD-1 x PD-L1) IND submission targeted Q3 2023 with Phase 1 start in Q4 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Compass Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share, EPS $0.09 per common share.

Period: the second quarter ended June 30, 2023
Net income: Net loss for the second quarter ended June 30, 2023 was $11.3 million or $0.09 per common share
EPS: $0.09 per common share
Result: reported results

Exact text from the filing

On August 3, 2023, Compass Therapeutics, Inc. issued a press release announcing financial results for the second quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-004946

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.